

Application No.: 10/714055

Docket No.: UMV-377CN6

AMENDMENTS TO THE CLAIMS

1-24 (Cancelled)

25. (New) A method of treating a patient having multiple sclerosis comprising administering to the patient soluble CTLA4 in an amount effective to suppress the patient's immune response.

26. (New) A method of treating a patient having systemic lupus erythematosis comprising administering to the patient soluble CTLA4 in an amount effective to suppress the patient's immune response.

27. (New) A method of treating a patient having rheumatoid arthritis comprising administering to the patient soluble CTLA4 in an amount effective to suppress the patient's immune response.

28. (New) A method of treating a patient having scleroderma comprising administering to the patient soluble CTLA4 in an amount effective to suppress the patient's immune response.

29. (New) The method of claim 25, further comprising the step of administering an additional immunosuppressant to the patient.

30. (New) The method of claim 26, further comprising the step of administering an additional immunosuppressant to the patient.

31. (New) The method of claim 27, further comprising the step of administering an additional immunosuppressant to the patient.

32. (New) The method of claim 28, further comprising the step of administering an additional immunosuppressant to the patient.

33. (New) The method of claim 29, wherein the additional immunosuppressant comprises cyclosporine.

34. (New) The method of claim 30, wherein the additional immunosuppressant comprises cyclosporine.

35. (New) The method of claim 31, wherein the additional immunosuppressant comprises cyclosporine.

36. (New) The method of claim 32, wherein the additional immunosuppressant comprises cyclosporine.

Application No.: 10/714055

Docket No.: UMV-377CN6

37. (New) The method of claim 29, wherein the soluble CTLA4 is administered to the patient parenterally.

38. (New) The method of claim 30, wherein the soluble CTLA4 is administered to the patient parenterally.

39. (New) The method of claim 31, wherein the soluble CTLA4 is administered to the patient parenterally.

40. (New) The method of claim 32, wherein the soluble CTLA4 is administered to the patient parenterally.